Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06945614 · ClinicalTrials.gov registry record · Phase 1
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
A Phase 1 study of Healthy Volunteer Study, sponsored by General Biophysics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06945614 is a Phase 1 study of Healthy Volunteer Study that is actively recruiting participants, run by General Biophysics. The registered enrollment target is 16 participants, below the 35-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06945614, a Phase 1 study of Healthy Volunteer Study, is actively recruiting participants, sponsored by General Biophysics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical study is to evaluate safety of Xenon gas inhalation in healthy volunteers. This first phase safety clinical study is part of evaluation of the xenon gas inhalation as a therapy for neurodegenerative diseases, such as Alzheimer's disease. The investigators will administer xenon gas in low concentration to people via anesthetic machine, observe participants for sedation and any unexpected side effects, collect blood at each visit and measure the vital signs. There are four treatment groups in the study, which correspond with the duration of xenon gas treatment. Individual participation will last approximately 14 days over five visits: screening visit accompanied by the electrocardiogram, blood, and urine test; treatment visit for xenon gas inhalation treatment; and three follow up visits.
Conditions Studied
Interventions
- DRUG Xenon gas inhalation
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06945614
The ClinicalTrials.gov registry entry for NCT06945614 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (54% lower). The listed sponsor is General Biophysics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteer Study appearing as the primary indexed condition, and to 1 intervention - of which Xenon gas inhalation is the first listed.
NCT06945614 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06945614 about?
NCT06945614 is a clinical study titled "Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation". The goal of this clinical study is to evaluate safety of Xenon gas inhalation in healthy volunteers. This first phase safety clinical study is part of evaluation of the xenon gas inhalation as a therapy for neurodegenerative diseases, such as Alzheimer's disease. The investigators will administer x...
What is the current status of trial NCT06945614?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-04-16. Estimated completion is 2025-12-31.
What conditions does trial NCT06945614 study?
This clinical trial studies the following conditions: Healthy Volunteer Study.
What interventions are being tested in trial NCT06945614?
The interventions under investigation include: Xenon gas inhalation (DRUG).
Who is sponsoring clinical trial NCT06945614?
This trial is sponsored by General Biophysics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06945614 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer Study
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects
COMPLETED · Phase 1
-
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
COMPLETED · Phase 1
-
Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
COMPLETED · Phase 1
-
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
COMPLETED · Phase 1
-
Near-InfraRed Spectroscopy of Auricular Stimulation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.